MARC Record from marc_columbia

LEADER: 06965fam a2200409 a 4500
001 3985536
005 20221027013346.0
008 931115t19941994nyua b 001 0 eng c
010 $a 93045267
020 $a0824788249 (alk. paper)
035 $a(OCoLC)29430969
035 $a(OCoLC)ocm29430969
035 $9AJB4340HS
035 $a(NNC)3985536
035 $a3985536
040 $aDNLM/DLC$cDLC$dDLC$dNNC-M$dOrLoB-B
050 00 $aRC935.S64$bT48 1994
060 00 $aW1 NE33LD v.25 1994$aQV 132 T3985 1994
082 00 $a616.7/4061$220
245 00 $aTherapy with botulinum toxin /$cedited by Joseph Jankovic, Mark Hallett.
260 $aNew York :$bM. Dekker,$c[1994], ©1994.
300 $axxvi, 608 pages :$billustrations ;$c26 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
490 1 $aNeurological disease and therapy ;$v25
504 $aIncludes bibliographical references and index.
505 20 $tSeries Introduction /$rWilliam C. Koller -- $tForeword /$rAlan B. Scott -- $tHistorical Perspective /$rEdward J. Schantz -- $g1.$tThe Site and Mechanism of Action of Botulinum Neurotoxin /$rJulie A. Coffield, Robert V. Considine and Lance L. Simpson -- $g2.$tStructures of Botulinum Neurotoxin, Its Functional Domains, and Perspectives on the Crystalline Type A Toxin /$rBibhuti R. DasGupta -- $g3.$tPreparation and Characterization of Botulinum Toxin Type A for Human Treatment /$rEdward J. Schantz and Eric A. Johnson -- $g4.$tTheoretical Analyses of the Functional Regions of the Heavy Chain of Botulinum Neurotoxin /$rFrank J. Lebeda, Dallas C. Hack and Mary K. Gentry -- $g5.$tEvaluation of Captopril and Other Potential Therapeutic Compounds in Antagonizing Botulinum Toxin-Induced Muscle Paralysis /$rMichael Adler, Sharad S. Deshpande, Robert E. Sheridan and Frank J. Lebeda -- $g6.$tBotulinum Toxin Type B: Experimental and Clinical Experience /$rElizabeth Moyer and Paulette E. Setler -- $g7.$tProduction and Properties of Type F Toxin /$rTomoko Shimizu and Genji Sakaguchi -- $g8.$tImmunogenicity of the Neurotoxins of Clostridium botulinum /$rCharles L. Hatheway and Carol Dang -- $g9.$tSystemic Effects of Botulinum Toxin /$rDale J. Lange -- $g10.$tPharmacology and Histology of the Therapeutic Application of Botulinum Toxin /$rGary E. Borodic, Robert J. Ferrante, L. Bruce Pearce and Kathy Alderson -- $g11.$tAssessment of the Biological Activity of Botulinum Toxin /$rChristopher M. Shaari and Ira Sanders -- $g12.$tDystonia /$rStanley Fahn -- $g13.$tBotulinum Toxin for Blepharospasm /$rJohn S. Elston -- $g14.$tAcute and Chronic Effects of Botulinum Toxin in the Management of Blepharospasm /$rJonathan J. Dutton -- $g15.$tClinical Assessments of Patients with Cervical Dystonia /$rEarl S. Consky and Anthony E. Lang -- $g16.$tAnatomy and Neurophysiology of Neck Muscles /$rRichard M. Dubinsky -- $g17.$tClinical Neurophysiology of Cervical Dystonia /$rMichael J. Aminoff and Richard K. Olney -- $g18.$tExperience with Botulinum Toxin in Cervical Dystonia /$rW. Poewe and Jorg Wissel -- $g19.$tControlled Trials of Botulinum Toxin for Cervical Dystonia: A Critical Review /$rPaul Greene -- $g20.$tElectromyography-Assisted Botulinum Toxin Injections for Cervical Dystonia /$rCynthia L. Comella -- $g21.$tBotulinum Toxin Treatment of Focal Hand Dystonia /$rBarbara Illowsky Karp and Mark Hallett -- $g22.$tLimb Dystonia: Treatment with Botulinum Toxin /$rSeth L. Pullman -- $g23.$tClinical Experience with Botulinum Toxin F /$rKaren Rhew, Christy L. Ludlow and Barbara Illowsky Karp -- $g24.$tHemifacial Spasm: Evaluation and Management, with Emphasis on Botulinum Toxin Therapy /$rGary E. Borodic -- $g25.$tManagement of Hemifacial Spasm with Botulinum A Toxin /$rAlbert W. Biglan and Sang-Jin Kim -- $g26.$tBotulinum Toxin for Facial-Oral-Mandibular Spasms and Bruxism /$rAlfredo Berardelli, Bruno Mercuri and Alberto Priori -- $g27.$tClinical Use of Botulinum Toxin: Clinical Trials for Strabismus /$rElbert H. Magoon -- $g28.$tStrabismus: Other Therapies /$rOscar A. Cruz and John T. Flynn -- $g29.$tManagement of Acute and Chronic VI Nerve Palsy /$rArthur L. Rosenbaum -- $g30.$tClinical Aspects of Speech Motor Compromise /$rDavid B. Rosenfield -- $g31.$tAcoustic, Aerodynamic, and Videoendoscopic Assessment of Unilateral Thyroarytenoid Muscle Injection with Botulinum Toxin for Spasmodic Dysphonia /$rGayle E. Woodson, Thomas Murry, Petra Zwirner and Michael R. Swenson -- $g32.$tOromandibular Dystonia: Treatment of 96 Patients with Botulinum Toxin Type A /$rMitchell F. Brin, Andrew Blitzer, Susan Herman and Celia Stewart -- $g33.$tBotulinum Toxin Injection for Adductor Spasmodic Dysphonia /$rChristy L. Ludlow, Karen Rhew and Eric Anthony Nash -- $g34.$tThe Evaluation and Management of Abductor Laryngeal Dysphonia /$rAndrew Blitzer and Mitchell F. Brin -- $g35.$tIndirect Laryngoscopic Approach for Injection of Botulinum Toxin in Spasmodic Dysphonia /$rCharles N. Ford -- $g36.$tUnilateral Injections of Botulinum Toxin in Spasmodic Dysphonia /$rDonald T. Donovan, Kenneth Schwartz and Joseph Jankovic -- $g37.$tResponses of Stutterers and Vocal Tremor Patients to Treatment with Botulinum Toxin /$rSheila V. Stager and Christy L. Ludlow -- $g38.$tTreatment of Tremors with Botulinum Toxin /$rJoseph Jankovic -- $g39.$tBotulinum Toxin in the Treatment of Tics /$rJoseph Jankovic -- $g40.$tBotulinum Toxin: Potential Role in the Management of Cerebral Palsy During Childhood /$rL. Andrew Koman, James F. Mooney III and Beth Paterson Smith -- $g41.$tClinical Trials for Spasticity /$rJoseph King Ching Tsui and Christopher F. O'Brien -- $g42.$tEffects of Botulinum Toxin Type A on Detrusor-Sphincter Dyssynergia in Spinal Cord Injury Patients /$rDennis D. Dykstra -- $g43.$tBotulinum Toxin in the Treatment of Gastrointestinal Disorders /$rPankaj Jay Pasricha and Anthony N. Kalloo -- $g44.$tBotulinum Toxin for Spasms and Spasticity in the Lower Extremities /$rReiner Benecke -- $g45.$tBotulinum Toxin Treatment of Palatal Tremor (Myoclonus) /$rGunther Deuschl, E. Lohle, Camilo Toro, Mark Hallett and Robert S. Lebovics -- $g46.$tBotulinum Toxin in the Treatment of Glabellar Frown Lines and Other Facial Wrinkles /$rAlastair Carruthers and Jean D. A. Carruthers.
650 0 $aBotulinum toxin$xTherapeutic use.$0http://id.loc.gov/authorities/subjects/sh2009117483
650 0 $aSpasms$xChemotherapy.
650 0 $aDystonia$xChemotherapy.
650 0 $aVoice disorders$xChemotherapy.
650 2 $aBotulinum Toxins$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D001905Q000627
650 2 $aMuscular Diseases$xdrug therapy.$0https://id.nlm.nih.gov/mesh/D009135Q000188
700 1 $aJankovic, Joseph.$0http://id.loc.gov/authorities/names/n84176324
700 1 $aHallett, Mark,$d1943-$0http://id.loc.gov/authorities/names/no2007004422
830 0 $aNeurological disease and therapy ;$vv. 25.$0http://id.loc.gov/authorities/names/n86728765
852 00 $boff,hsl$hRC935.S64$iT48 1994